[1] Shiravand Y, Khodadadi F, Kashani S, et al. Immune checkpoint inhibitors in cancer therapy[J].Curr Oncol,2022,29(5):3044-3060. DOI: 10.3390/curroncol29050247. [2] Vere J, Gibson B. Evidence-based medicine as science[J].J Eval Clin Pract,2019,25(6):997-1002. DOI: 10.1111/jep.13090. [3] Freddi G, Romàn-Pumar JL. Evidence-based medicine: what it can and cannot do[J].Ann Ist Super Sanita,2011,47(1):22-25. DOI: 10.4415/ANN_11_01_06. [4] Labrie M, Brugge JS, Mills GB, et al. Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer[J].Nat Rev Cancer,2022,22(6):323-339. DOI: 10.1038/s41568-022-00454-5. [5] Ciardiello F, Ciardiello D, Martini G, et al. Clinical management of metastatic colorectal cancer in the era of precision medicine[J].CA Cancer J Clin,2022,72(4):372-401. DOI: 10.3322/caac.21728. [6] Rodrigues-Ferreira S, Nahmias C. Predictive biomarkers for personalized medicine in breast cancer[J].Cancer Lett,2022,545:215828. DOI: 10.1016/j.canlet.2022.215828. [7] 王鹏, 江晓华, 耿浩非, 等. 迷你临床演练评估在肿瘤专科医师规范化培训中的应用[J].重庆医学,2021,50(12):2149-2152. DOI: 10.3969/j.issn.1671-8348.2021.12.038. [8] 姚榕, 周磊磊, 岳顺, 等. PBL联合MDT的教学模式在肿瘤专科医师规范化培训中的应用[J].继续医学教育,2019,33(3):43-44. DOI: 10.3969/j.issn.1004-6763.2019.03.023. [9] 石岩岩, 何旋, 卢贵胜, 等. 医学生见习阶段循证临床实践课程的设计和实施[J].中华医学教育杂志,2022,42(4):305-308. DOI: 10.3760/cma.j.cn115259-20210903-01117. [10] 姚亚妮, 王玉玲, 杨新玲. 临床研究生循证医学教学改革实践[J].中华医学教育探索杂志,2015(2):155-157. DOI: 10.3760/cma.j.issn.2095-1485.2015.02.012. [11] 陈亚男, 阮晓岚, 欧阳雯, 等. PBL结合EBM教学在住院医师规范化培训中应用的系统评价[J]. 中华医学教育探索杂志, 2022,21(6):722-726.DOI: 10.3760/cma.j.cn116021-20200601-00888. [12] Mehmi I, Hamid O. Immunotherapy of cancer in the era of checkpoint inhibitor[J].Clin Exp Metastasis,2022,39(1):231-237. DOI: 10.1007/s10585-021-10132-9. [13] Wu Z, Chen Q, Qu L, et al. Adverse events of immune checkpoint inhibitors therapy for urologic cancer patients in clinical trials: a collaborative systematic review and meta-analysis[J]. Eur Urol,2022,81(4):414-425. DOI: 10.1016/j.eururo.2022.01.028. [14] Morganti S, Tarantino P, Ferraro E, et al. Next generation sequencing (NGS): a revolutionary technology in pharmacogenomics and personalized medicine in cancer[J].Adv Exp Med Biol,2019,1168:9-30. DOI: 10.1007/978-3-030-24100-1_2. [15] Schiavenato M, Chu F. PICO: What it is and what it is not[J].Nurse Educ Pract,2021,56:103194. DOI: 10.1016/j.nepr.2021.103194. [16] 周登远, 汪培山. 临床对照试验文献质量评价的发展与现状[J].药物流行病学杂志,2004,13(4):211-214. DOI: 10.3969/j.issn.1005-0698.2004.04.017. [17] Filleron T, Gilhodes J, Delord JP, et al. Subgroup analysis and forest plots: limitations and interests[J].Bull Cancer,2017,104(1):92-100. DOI: 10.1016/j.bulcan.2016.09.023. |